Monday July 13, 2020

New formula for success?

There's a new $7.3 billion hostile bid on the table for Elan, but what are the key considerations for its thousands of Irish shareholders, asks Richard Curran.

20th April, 2013
Elan chief executive G Kelly Martin: many observers believe he needs to completely reinvent the company. Photo: Tony O'Shea


After selling Elan's share in Tysabri, its multiple sclerosis drug, Martin is using the €3.25 billion in proceeds to reinvent the firm as a private equity-style acquisition vehicle - a high risk gamble sweetened with a recent €1 billion share buyback


Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 6 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago